Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Infectious diseases · Lancet Infect Dis · 2026-05-06
RCTn = 221 infants
Thorn et al. Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trialInfectious diseases · Lancet Microbe · 2026-02-13
RCTn = 407
Liatsikos et al. The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trialInfectious diseases · Vaccine · 2026-01-22
Secondary analysisn = 65
Tembo et al. 13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adultsInfectious diseases · Vaccine · 2026-01-18
RCTn = 1,800
Shi et al. Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III studyInfectious diseases · Vaccine · 2026-01-06
Secondary analysisn = 1,342
Martinez-de-Albeniz et al. Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial